Vimta Labs Limited VIMTALABS NSEPHARMA
Vimta Labs Limited provides contract research and testing services in India and internationally. The company offers drug discovery, development, and drug life cycle management support services in the areas of preclinical research, clinical research, and analytical services for biopharmaceutical companies; preclinical research and testing services for medical device companies; and contract research and testing for agrochemical and specialty chemical companies. It also provides food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, and regulators; and a testing laboratory for water, alcoholic, and non-alcoholic beverages. In addition, the company offers environmental regulatory services, such as impact assessments and post project monitoring, to various industries, including power, infrastructure, cement, oil and gas, and mining, etc.; and EMI/EMC testing for electronic and electrical products/components. It provides solutions to agriculture, biologics and biosimilars, home and personal care, medical device, specialty chemicals, food, electrical and electronics, nutraceuticals, water and beverages, pharmaceuticals, crop care, environment, health and safety, and packaging industries. Vimta Labs Limited was founded in 1984 and is headquartered in Hyderabad, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Healthy ROCE of 21.2%.
- Profit CAGR of 17.2% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 46.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VIMTALABS Vimta Labs Limited NSEPHARMA | 469.70 | 27.32 | ₹2,103.45 Cr | 0.43% | 21.16% | 18.55% | 8.94% | 17.18% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,799.20 | 37.59 | ₹4.32 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,667.00 | 68.97 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,410.80 | 68.96 | ₹1.49 L Cr | 0.86% | 9.06% | 16.98% | 13.27% | 20.21% |
| 5 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,401.00 | 29.16 | ₹1.13 L Cr | 0.93% | 14.88% | 11.74% | 7.23% | 11.45% |
| 6 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,303.50 | 25.90 | ₹1.09 L Cr | 0.61% | 14.00% | 11.83% | 10.96% | -2.35% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,077.70 | 21.51 | ₹1.08 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,267.70 | 19.49 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
| 9 | MANKIND Mankind Pharma Limited NIFTY_MIDNSEPHARMA | 2,375.60 | 51.29 | ₹98,090.71 Cr | 0.08% | 13.78% | 12.45% | 17.73% | 14.28% |
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 94.44 Cr | 97.56 Cr | 101.85 Cr | 98.63 Cr | 109.25 Cr |
| Cost of Revenue | 18.18 Cr | 18.81 Cr | 20.15 Cr | 19.36 Cr | 22.48 Cr |
| Gross Profit | 76.26 Cr | 78.75 Cr | 81.70 Cr | 79.27 Cr | 86.77 Cr |
| Operating Expenses | 52.44 Cr | 54.93 Cr | 57.71 Cr | 55.96 Cr | 60.15 Cr |
| Operating Income | 23.82 Cr | 23.83 Cr | 23.99 Cr | 23.31 Cr | 26.62 Cr |
| EBITDA | 34.68 Cr | 35.44 Cr | 36.89 Cr | 34.45 Cr | 42.12 Cr |
| Interest Expense | 43.80 L | 31.50 L | 37.40 L | 15.70 L | 32.10 L |
| Pretax Income | 25.03 Cr | 25.26 Cr | 26.27 Cr | 23.37 Cr | 29.05 Cr |
| Tax Provision | 6.71 Cr | 6.37 Cr | 6.35 Cr | 5.79 Cr | 7.93 Cr |
| Net Income | 18.32 Cr | 18.89 Cr | 19.92 Cr | 17.59 Cr | 21.11 Cr |
| Diluted EPS | 4.04 | 4.21 | 4.44 | 3.94 | 4.62 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 315.06 Cr | 288.60 Cr | 343.98 Cr | 407.29 Cr |
| Cost of Revenue | - | 73.85 Cr | 57.66 Cr | 71.45 Cr | 80.79 Cr |
| Gross Profit | - | 241.21 Cr | 230.94 Cr | 272.54 Cr | 326.50 Cr |
| Operating Expenses | - | 171.53 Cr | 166.48 Cr | 185.88 Cr | 228.75 Cr |
| Operating Income | - | 69.68 Cr | 64.46 Cr | 86.66 Cr | 97.75 Cr |
| EBITDA | - | 96.64 Cr | 98.22 Cr | 126.63 Cr | 148.89 Cr |
| Interest Expense | - | 92.80 L | 1.52 Cr | 1.90 Cr | 1.17 Cr |
| Pretax Income | - | 65.00 Cr | 62.50 Cr | 89.00 Cr | 103.95 Cr |
| Tax Provision | - | 16.82 Cr | 13.69 Cr | 22.25 Cr | 26.44 Cr |
| Net Income | - | 48.17 Cr | 41.01 Cr | 67.34 Cr | 77.51 Cr |
| Diluted EPS | - | 10.68 | 9.12 | 14.93 | 17.20 |
Compounded Sales Growth
| 5 Years: | 8.94% |
| 1 Year: | 14.00% |
Compounded Profit Growth
| 5 Years: | 17.18% |
| 1 Year: | 18.20% |
Stock Price Performance
| 1 Year: | -4.18% |
| 6 Months: | -23.58% |
| 3 Months: | +1.61% |
| 1 Month: | +2.75% |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 362.32 Cr | 394.47 Cr | 466.53 Cr | 562.23 Cr |
| Current Assets | - | 163.66 Cr | 157.60 Cr | 187.82 Cr | 224.87 Cr |
| Cash & Equivalents | - | 30.50 Cr | 13.44 Cr | 15.84 Cr | 22.97 Cr |
| Inventory | - | 22.62 Cr | 24.69 Cr | 25.06 Cr | 29.95 Cr |
| Receivables | - | 79.99 Cr | 87.00 Cr | 106.24 Cr | 105.70 Cr |
| Total Liabilities | - | 80.54 Cr | 80.35 Cr | 87.68 Cr | 105.36 Cr |
| Current Liabilities | - | 57.28 Cr | 54.07 Cr | 64.37 Cr | 65.52 Cr |
| Long Term Debt | - | 9.89 Cr | 9.07 Cr | 3.22 Cr | 1.56 Cr |
| Total Debt | - | 14.99 Cr | 19.19 Cr | 8.52 Cr | 3.33 Cr |
| Total Equity | - | 281.79 Cr | 314.12 Cr | 378.85 Cr | 456.87 Cr |
| Shares Outstanding | - | 4.43 Cr | 4.43 Cr | 4.45 Cr | 4.47 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 87.94 Cr | 60.89 Cr | 94.05 Cr | 147.14 Cr |
| Investing Cash Flow | - | -57.26 Cr | -76.05 Cr | -75.54 Cr | -129.67 Cr |
| Financing Cash Flow | - | -10.98 Cr | -1.90 Cr | -16.12 Cr | -10.35 Cr |
| Capital Expenditure | - | -49.80 Cr | -76.57 Cr | -79.49 Cr | -99.80 Cr |
| Free Cash Flow | - | 38.13 Cr | -15.68 Cr | 14.56 Cr | 47.34 Cr |
| Net Change in Cash | - | 19.70 Cr | -17.06 Cr | 2.40 Cr | 7.12 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 76.6% | 80.0% | 79.2% | 80.2% |
| Operating Margin % | - | 22.1% | 22.3% | 25.2% | 24.0% |
| Net Margin % | - | 15.3% | 14.2% | 19.6% | 19.0% |
| ROE % | - | 17.1% | 13.1% | 17.8% | 17.0% |
| ROCE % | - | 22.8% | 18.9% | 21.5% | 19.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VIMTALABS